Notch signaling is crucial for lymphocyte effector and memory differentiation. While tumor suppress Notch signaling in antitumor lymphocytes, recent studies show that the pharmacological Delta-like ligand-1 multivalent cluster or proteasome inhibitor bortezomib can restore Notch-NF-κB signaling in T cells of tumor-bearing hosts with a potential to overcome cancer cell resistance to therapy.
Keywords: Adoptive T cell therapy; Delta-like ligands; Notch signaling; antitumor immunity; bortezomib; cancer immunotherapy; immunosuppression.